Pfizer (NYSE:PFE) Earns “Buy” Rating from Credit Suisse Group

Pfizer (NYSE:PFE)‘s stock had its “buy” rating reissued by research analysts at Credit Suisse Group in a report issued on Monday, May 6th, Stock Target Advisor reports. They currently have a $48.00 price objective on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective would suggest a potential upside of 14.56% from the stock’s current price.

PFE has been the subject of a number of other research reports. Cantor Fitzgerald restated a “buy” rating and set a $53.00 price objective on shares of Pfizer in a research report on Tuesday, February 19th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research report on Thursday, January 31st. Bank of America lifted their price target on Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. Finally, ValuEngine lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Thirteen research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $45.83.

Shares of NYSE PFE traded up $0.18 during midday trading on Monday, hitting $41.90. 16,123,148 shares of the stock traded hands, compared to its average volume of 23,054,374. Pfizer has a one year low of $35.32 and a one year high of $46.47. The stock has a market capitalization of $249.43 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 2.42 and a beta of 0.71. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.10. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. The company had revenue of $13.12 billion for the quarter, compared to analysts’ expectations of $13.01 billion. During the same period last year, the firm earned $0.77 EPS. Pfizer’s revenue for the quarter was up 1.6% compared to the same quarter last year. Equities research analysts anticipate that Pfizer will post 2.89 EPS for the current year.

In other news, insider Rady A. Johnson sold 8,700 shares of Pfizer stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $41.13, for a total transaction of $357,831.00. Following the completion of the sale, the insider now owns 59,797 shares of the company’s stock, valued at $2,459,450.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mikael Dolsten sold 100,471 shares of Pfizer stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $43.56, for a total transaction of $4,376,516.76. Following the sale, the insider now directly owns 390,097 shares of the company’s stock, valued at approximately $16,992,625.32. The disclosure for this sale can be found here. In the last three months, insiders sold 288,726 shares of company stock valued at $12,534,617. 0.09% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the company. First Command Financial Services Inc. grew its holdings in Pfizer by 8.4% in the third quarter. First Command Financial Services Inc. now owns 31,470 shares of the biopharmaceutical company’s stock worth $1,386,000 after purchasing an additional 2,448 shares during the last quarter. Harwood Advisory Group LLC grew its holdings in Pfizer by 16.3% in the third quarter. Harwood Advisory Group LLC now owns 52,684 shares of the biopharmaceutical company’s stock worth $2,321,000 after purchasing an additional 7,403 shares during the last quarter. Stillwater Capital Advisors LLC grew its holdings in Pfizer by 0.8% in the third quarter. Stillwater Capital Advisors LLC now owns 375,750 shares of the biopharmaceutical company’s stock worth $16,559,000 after purchasing an additional 2,863 shares during the last quarter. Spinnaker Trust grew its holdings in Pfizer by 5.5% in the third quarter. Spinnaker Trust now owns 76,433 shares of the biopharmaceutical company’s stock worth $3,368,000 after purchasing an additional 3,991 shares during the last quarter. Finally, Telemus Capital LLC grew its holdings in shares of Pfizer by 12.8% during the third quarter. Telemus Capital LLC now owns 72,129 shares of the biopharmaceutical company’s stock valued at $3,179,000 after buying an additional 8,205 shares during the last quarter. 67.17% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: What are retained earnings?

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.